1 | ONCSSF4 ;Hines OIFO/GWB - SITE-SPECIFIC FACTOR 4 (165.5,44.4) ;11/20/03
|
---|
2 | ;;2.11;ONCOLOGY;**40**;Mar 07, 1995
|
---|
3 | ;
|
---|
4 | ;SITE-SPECIFIC FACTOR 4 (165.5,44.4)
|
---|
5 | SSF4IT ;INPUT TRANSFORM
|
---|
6 | ;
|
---|
7 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
|
---|
8 | I PS="" K X W " No PRIMARY SITE defined for this primary" Q
|
---|
9 | S MO=$$HIST^ONCFUNC(D0)
|
---|
10 | ;
|
---|
11 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-4")):$O(^ONCO(164.52,"C",PS_"-4",0)),1:1)
|
---|
12 | ;
|
---|
13 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
|
---|
14 | I $$MELANOMA^ONCOU55(D0) D
|
---|
15 | .S MELIEN=$O(^ONCO(164.52,"B","LDH",0))
|
---|
16 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
|
---|
17 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
|
---|
18 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
|
---|
19 | .I PS=67632 S SSFIEN=MELIEN Q
|
---|
20 | ;
|
---|
21 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
|
---|
22 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
23 | ;
|
---|
24 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
|
---|
25 | ;Kaposi Sarcoma of All Sites
|
---|
26 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
27 | ;
|
---|
28 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
|
---|
29 | ;Myeloproliferative Neoplasms
|
---|
30 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
31 | ;
|
---|
32 | ;Retinoblastoma
|
---|
33 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
34 | ;
|
---|
35 | I '$D(^ONCO(164.52,SSFIEN,1,"B",X)) K X Q
|
---|
36 | S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",X,0))
|
---|
37 | W " ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2)
|
---|
38 | ITEX K PS,SSFIEN,SSF,MO,MELING Q
|
---|
39 | ;
|
---|
40 | SSF4OT ;OUTPUT TRANSFORM
|
---|
41 | ;
|
---|
42 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
|
---|
43 | Q:PS=""
|
---|
44 | S MO=$$HIST^ONCFUNC(D0)
|
---|
45 | ;
|
---|
46 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-4")):$O(^ONCO(164.52,"C",PS_"-4",0)),1:1)
|
---|
47 | ;
|
---|
48 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
|
---|
49 | I $$MELANOMA^ONCOU55(D0) D
|
---|
50 | .S MELIEN=$O(^ONCO(164.52,"B","LDH",0))
|
---|
51 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
|
---|
52 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
|
---|
53 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
|
---|
54 | .I PS=67632 S SSFIEN=MELIEN Q
|
---|
55 | ;
|
---|
56 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
|
---|
57 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
58 | ;
|
---|
59 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
|
---|
60 | ;Kaposi Sarcoma of All Sites
|
---|
61 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
62 | ;
|
---|
63 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
|
---|
64 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
65 | ;
|
---|
66 | ;Retinoblastoma
|
---|
67 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
68 | ;
|
---|
69 | S SSF=$O(^ONCO(164.52,SSFIEN,1,"B",Y,0)) I SSF="" G OTEX
|
---|
70 | S Y=$P($G(^ONCO(164.52,SSFIEN,1,SSF,0)),U,2)
|
---|
71 | OTEX K PS,SSFIEN,SSF,MO Q
|
---|
72 | ;
|
---|
73 | SSF4HP ;HELP
|
---|
74 | ;
|
---|
75 | S PS=$P($G(^ONCO(165.5,D0,2)),U,1)
|
---|
76 | Q:PS=""
|
---|
77 | S MO=$$HIST^ONCFUNC(D0)
|
---|
78 | ;
|
---|
79 | S SSFIEN=$S($D(^ONCO(164.52,"C",PS_"-4")):$O(^ONCO(164.52,"C",PS_"-4",0)),1:1)
|
---|
80 | ;
|
---|
81 | ;Malignant Melanoma of Skin, Vulva, Penis, Scrotum
|
---|
82 | I $$MELANOMA^ONCOU55(D0) D
|
---|
83 | .S MELIEN=$O(^ONCO(164.52,"B","LDH",0))
|
---|
84 | .I $E(PS,3,4)=44 S SSFIEN=MELIEN Q
|
---|
85 | .I $E(PS,3,4)=51 S SSFIEN=MELIEN Q
|
---|
86 | .I $E(PS,3,4)=60 S SSFIEN=MELIEN Q
|
---|
87 | .I PS=67632 S SSFIEN=MELIEN Q
|
---|
88 | ;
|
---|
89 | ;Hodgkin and Non-Hodgkin Lymphomas of All Sites
|
---|
90 | I $$LYMPHOMA^ONCFUNC(D0) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
91 | ;
|
---|
92 | ;Mycosis Fungoides and Sezary Disease of Skin, Vulva, Penis, Scrotum
|
---|
93 | ;Kaposi Sarcoma of All Sites
|
---|
94 | I (MO=97003)!(MO=97013)!($E(MO,1,4)=9140) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
95 | ;
|
---|
96 | ;Hematopoietic, Reticuloendothelial, Immunoproliferative, and
|
---|
97 | I (MO'<97310)&(MO'>99899) S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
98 | ;
|
---|
99 | ;Retinoblastoma
|
---|
100 | I $E(MO,1,3)=951 S SSFIEN=$O(^ONCO(164.52,"B","NOT APPLICABLE FOR THIS SITE",0))
|
---|
101 | ;
|
---|
102 | W !," SITE-SPECIFIC FACTOR 4 for " D
|
---|
103 | .I MO=97003 W "MYCOSIS FUNGOIDES of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
104 | .I MO=97013 W "SEZARY SYNDROME of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
105 | .I $E(MO,1,3)=951 W "RETINOBLASTOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
106 | .I $$MELANOMA^ONCOU55(D0),($E(PS,3,4)=44)!($E(PS,3,4)=51)!($E(PS,3,4)=60)!(PS=67632)!($E(PS,3,4)=69) W "MALIGNANT MELANOMA of ",$P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")" Q
|
---|
107 | .I $E(MO,1,4)=9140 W "KAPOSI SARCOMA of ALL SITES" Q
|
---|
108 | .I $$LYMPHOMA^ONCFUNC(D0) W "HODGKIN AND NON-HODGKIN LYMPHOMAS of ALL SITES" Q
|
---|
109 | .I (MO'<97310)&(MO'>99899) W $P(^ONCO(169.3,MO,0),U,1)," (",$P(^ONCO(169.3,MO,0),U,2),")" Q
|
---|
110 | .W $P(^ONCO(164,PS,0),U,1)," (",$P(^ONCO(164,PS,0),U,2),")"
|
---|
111 | W !," ",$P(^ONCO(164.52,SSFIEN,0),U,1)
|
---|
112 | ;S SSF=0 F S SSF=$O(^ONCO(164.52,SSFIEN,1,SSF)) Q:SSF'>0 D
|
---|
113 | ;.S TAB=6
|
---|
114 | ;.W " ",$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,1),?TAB,$P(^ONCO(164.52,SSFIEN,1,SSF,0),U,2),!
|
---|
115 | K PS,SSFIEN,SSF,MO Q
|
---|